Empyema Treated With tPA & DNAse
| Status: | Withdrawn |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any - 17 |
| Updated: | 4/21/2016 |
| Start Date: | January 2016 |
| End Date: | January 2016 |
Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis
compared to our standard tPA.
The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the
addition of DNAse.
The primary outcome variable between the two techniques will be length of hospitalization
after initiation of treatment.
compared to our standard tPA.
The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the
addition of DNAse.
The primary outcome variable between the two techniques will be length of hospitalization
after initiation of treatment.
Inclusion Criteria:
Patients less than 18 years of age requiring an intervention for empyema by one of the
following:
- Septation or loculation seen on ultrasound or computed tomography or
- Greater than 10,000 white blood cells identified on pleural tap
Exclusion Criteria:
- Immunodeficiency process
- Secondary diagnosis or condition that will keep them in the hospital beyond the
empyema
- Existing contraindications to chest tube
- Documented allergy to one of the study medications
We found this trial at
1
site
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
Click here to add this to my saved trials
